ATH Stock Overview
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Alterity Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.003 |
| 52 Week High | AU$0.009 |
| 52 Week Low | AU$0.002 |
| Beta | 0.68 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -25.00% |
| 33 Year Change | -88.89% |
| 5 Year Change | -88.46% |
| Change since IPO | -98.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -14.3% | -3.6% | 1.5% |
| 1Y | -25.0% | 10.0% | 17.2% |
Return vs Industry: ATH underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: ATH underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| ATH volatility | |
|---|---|
| ATH Average Weekly Movement | 37.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ATH's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ATH's weekly volatility has increased from 31% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 10 | David Stamler | alteritytherapeutics.com |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.
Alterity Therapeutics Limited Fundamentals Summary
| ATH fundamental statistics | |
|---|---|
| Market cap | AU$15.96m |
| Earnings (TTM) | -AU$19.12m |
| Revenue (TTM) | AU$4.02m |
4.0x
P/S Ratio-0.8x
P/E RatioIs ATH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATH income statement (TTM) | |
|---|---|
| Revenue | AU$4.02m |
| Cost of Revenue | AU$214.30k |
| Gross Profit | AU$3.80m |
| Other Expenses | AU$22.93m |
| Earnings | -AU$19.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0036 |
| Gross Margin | 94.67% |
| Net Profit Margin | -475.79% |
| Debt/Equity Ratio | 0% |
How did ATH perform over the long term?
See historical performance and comparison